On 2018-06-13, the U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab). This approval, identified as BLA 125514 S-30, was specifically based on demonstrated efficacy.
Background
Keytruda (pembrolizumab) is an established immunotherapy. This supplemental application concerned its efficacy, indicating an expansion of its approved therapeutic uses. The sponsor for this application was MERCK SHARP DOHME.
What this means
This supplemental FDA approval for Keytruda (pembrolizumab), specifically based on efficacy data, indicates an expansion of the drug's approved therapeutic applications. Such approvals typically mean that the drug has demonstrated significant benefits in a new patient population, for a new disease indication, or under specific new treatment conditions. For clinicians, this broadens the scope of patients who may benefit from pembrolizumab, offering additional treatment options where efficacy has been formally recognized by the FDA. For patients, it signifies increased access to an established immunotherapy for a newly approved use. The specific details of the expanded indication would be outlined in the updated prescribing information.
Source
The information regarding this supplemental FDA approval was sourced from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125514 S-30, concerning Keytruda (pembrolizumab), was recorded on 2018-06-13 on accessdata.fda.gov.